论文部分内容阅读
目的 研究肝细胞肝癌 (HCC)病人血清可溶性白细胞介素 2受体 (SIL - 2R)水平的变化情况及其临床意义。方法 用酶联免疫吸附试验方法 (ELISA)检测 60例HCC病人、3 0例良性肝胆疾病病人以及 2 0例健康对照者血清SIL - 2R水平 ,结合临床资料分析其临床意义。结果 HCC组血清SIL - 2R水平显著性高于其他两组 (P <0 .0 1) ,良性肝胆疾病组与健康对照组血清SIL - 2R水平无显著性差异 (P >0 .0 5 )。HCC组中血清SIL - 2R水平与疾病分期有较好的相关性 ,随HCC分期升高 ,SIL - 2R水平增高。血清SIL - 2R水平与AFP水平无相关性 (r=0 .197,P >0 .0 5 )。血清SIL - 2R水平可作为HCC早期诊断的良好指标 ,以 10 0pmol/L为切割值 ,其灵敏度为 81.7%,特异度为 10 0 %,诊断符合率 90 %。血清SIL - 2R水平变化受手术因素影响。术后SIL - 2R水平先升高后降低 ,降低程度与肿瘤切除与否有关。术后肿瘤复发病人血清SIL - 2R水平升高。结论 血清SIL - 2R水平可作为HCC病人早期诊断、病情判断、复发监测的重要指标。
Objective To study the changes of serum soluble interleukin - 2 receptor (SIL - 2R) in patients with hepatocellular carcinoma (HCC) and its clinical significance. Methods Serum levels of SIL - 2R in 60 patients with HCC, 30 patients with benign hepatobiliary diseases and 20 healthy controls were detected by enzyme - linked immunosorbent assay (ELISA), and their clinical significance was analyzed based on clinical data. Results The serum levels of SIL - 2R in HCC group were significantly higher than those in the other two groups (P <0.01). There was no significant difference in serum SIL - 2R between HCC group and healthy control group (P> 0.05). There was a good correlation between the level of SIL - 2R and the stage of disease in HCC group. The level of SIL - 2R increased with the increase of HCC staging. There was no correlation between serum SIL - 2R level and AFP level (r = 0.197, P> 0.05). Serum SIL - 2R levels can be used as a good indicator of early diagnosis of HCC. The cutoff value of 100 pmol / L has a sensitivity of 81.7% and a specificity of 10%. The diagnostic coincidence rate is 90%. Changes of serum SIL - 2R levels are influenced by surgical factors. The level of SIL - 2R increased first and then decreased, and the degree of decrease correlated with tumor resection or not. Postoperative tumor recurrence in patients with elevated serum levels of SIL - 2R. Conclusion Serum SIL - 2R level can be used as an important index for the early diagnosis, disease judgment and relapse monitoring of HCC patients.